![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.
Lead Product(s): IDP-023,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: IDP-023
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CPRIT
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Funding May 21, 2024
Details:
IDP-023 is an allogeneic G-NK cell therapy, which is being evaluated for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.
Lead Product(s): IDP-023,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: IDP-023
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
IDP-023 is a natural killer (NK) cell therapy which is currently being investigated in phase 1/2 clinical studies for the treatment of multiple myeloma and Non-Hodgkin’s lymphoma.
Lead Product(s): IDP-023,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: IDP-023
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Details:
The financing will be used for the first-in-human phase 1 trial of DP-023, an Allogeneic Natural Killer (NK) Cell Therapy in patients with multiple myeloma and lymphoma.
Lead Product(s): IDP-023,Antibody
Therapeutic Area: Oncology Product Name: IDP-023
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Leaps by Bayer
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 17, 2023
Details:
The company will use the proceeds of the financing to grow the team and continue to advance its universal, allogeneic NK cell platform toward an Investigational New Drug Application (IND) and clinical trials.
Lead Product(s): G-NK cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 10, 2022